Nitrofurantoin is a nitrofuran antibacterial that acts by inhibiting bacterial protein, DNA, RNA and cell wall synthesis. It is used in the treatment of uncomplicated lower urinary tract infections (UTIs), including prophylaxis or long-term suppressive therapy in recurrent infections.
After reading this article, pharmacists should be able to:
Competencies (2016) addressed: 1.1.3, 1.1.5, 1.3.1, 1.5.1, 1.5.3, 1.5.4, 1.6.1, 3.1.2, 3.2.3, 3.2.5, 3.4.1, 3.4.2, 3.4.3, 3.4.4, 3.4.8, 4.4.5, 4.5.2, 4.5.3.
Competencies (2010) addressed: 1.1.1, 1.2.1, 1.2.2, 1.4.1, 3.3.2, 3.4.1, 3.4.2, 4.2.1, 4.2.2, 4.2.3, 4.3.1, 4.3.3, 5.1.1, 5.1.2, 5.1.3, 5.1.4, 5.1.5, 5.1.6, 5.2.1, 7.1.4.
Nitrofurantoin is also indicated, although not as first-line treatment, for uncomplicated UTIs in children.
In Australia, nitrofurantoin is available as 50 mg and 100 mg capsules. A nitrofurantoin oral liquid is not marketed in Australia but may be available through the Special Access Scheme (SAS). For patients with difficulties swallowing capsules, a compounded oral liquid may be an appropriate alternative to mixing medicine with food or drink, which can make it difficult to assess how much of a dose has been taken, or provide convenient dosing for paediatric populations.
Want to learn more? PSA members can access the full article and assessment questions here to earn up to 1.5 Group 2 CPD credits.
Not a PSA member? Find out why more than 18,000 pharmacists choose PSA to support, advance and create opportunities for the pharmacy career and the greater pharmacy profession. Click here to join today.